Clinical Features and Prognosis of Primary Biliary Cirrhosis Associated with Systemic Sclerosis

Overview

Journal Gut

Specialty Gastroenterology

Date 2005 Sep 10

PMID 16150855

Citations 49

Authors

C Rigamonti

L M Shand

M Feudjo

C C Bunn

C M Black

C P Denton

A K Burroughs

Affiliations

Soon will be listed here.

Abstract

Backgrounds And Aims: To evaluate the prognosis of primary biliary cirrhosis (PBC) together with systemic sclerosis (SSc), as this is unknown.

Methods And Results: A PBC database of 580 patients identified 43 with PBC and SSc: two patients with PBC alone were matched to each PBC-SSc patient for serum bilirubin concentration at the initial visit. Forty (93%) patients had limited cutaneous SSc. At diagnosis of PBC, median values were: 49.7 years, bilirubin 17 micromol/l, and albumin 40.5 g/l. Liver diagnosis occurred a median 4.9 years after SSc in 24 (56%) patients. In matched patients, median values at diagnosis were: 53.2 years, bilirubin 12 micromol/l, and albumin 41 g/l. Median follow up was similar: 3.16 years (PBC-SSc) and 4.8 years (PBC alone). The risk of transplantation or death from diagnosis, adjusting for sex, age, log bilirubin, and alkaline phosphatase was significantly lower in PBC-SSc (hazard ratio 0.116, p=0.01) due to less transplantation (hazard ratio 0.068, p=0.006). The rate of bilirubin increase was less in PBC-SSc (p=0.04). Overall survival was similar (hazard ratio 1.11, p=0.948); there were nine deaths (21%) in PBC-SSc (six SSc related and two liver related) and nine (11%) in PBC alone (six liver related).

Conclusions: Liver disease has a slower progression in PBC-SSc compared with matched patients with PBC alone.

Citing Articles

Decreased prevalence and altered clinical phenotype of systemic sclerosis and other autoimmune connective tissue diseases in type 1 and type 2 diabetes: A cross-sectional observational study.

Abugharbyeh A, Khuder S, Kahaleh B J Scleroderma Relat Disord. 2024; :23971983241301231.

PMID: 39634481 PMC: 11613151. DOI: 10.1177/23971983241301231.

Cross-Phenotype GWAS Supports Shared Genetic Susceptibility to Systemic Sclerosis and Primary Biliary Cholangitis.

Luo Y, Khan A, Liu L, Lee C, Perreault G, Pomenti S medRxiv. 2024; .

PMID: 39006426 PMC: 11245064. DOI: 10.1101/2024.07.01.24309721.

Long-term outcomes in patients with primary biliary cholangitis complicated with CREST syndrome.

Abe K, Hayashi M, Sugaya T, Abe N, Takahata Y, Fujita M Sci Rep. 2024; 14(1):14124.

PMID: 38898064 PMC: 11187228. DOI: 10.1038/s41598-024-64976-8.

Genetic link between primary biliary cholangitis and connective tissue diseases in European populations: A two-sample Mendelian randomization study.

Liu Z, Shao Y, Duan X PLoS One. 2024; 19(2):e0298225.

PMID: 38335208 PMC: 10857725. DOI: 10.1371/journal.pone.0298225.

Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomes.

Lepri G, Airo P, Distler O, Andreasson K, Braun-Moscovici Y, Hachulla E J Scleroderma Relat Disord. 2023; 8(3):210-220.

PMID: 37744053 PMC: 10515998. DOI: 10.1177/23971983231155948.

References

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

Clarke A, Galbraith R, HAMILTON E, Williams R . Rheumatic disorders in primary biliary cirrhosis. Ann Rheum Dis. 1978; 37(1):42-7. PMC: 1000187. DOI: 10.1136/ard.37.1.42. View

Bernstein R, Callender M, Neuberger J, Hughes G, Williams R . Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis. 1982; 41(6):612-4. PMC: 1000995. DOI: 10.1136/ard.41.6.612. View

McCarty G, Rice J, Bembe M, Barada Jr F . Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum. 1983; 26(1):1-7. DOI: 10.1002/art.1780260101. View

Steen V, Ziegler G, Rodnan G, Medsger Jr T . Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984; 27(2):125-31. DOI: 10.1002/art.1780270202. View

Gupta R, Seibold J, Krishnan M, Steigerwald J . Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis. Clin Exp Immunol. 1984; 58(1):68-76. PMC: 1576963. View

Powell F, Winkelmann R, Spurbeck J, Schroeter A . The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc. 1984; 59(10):700-6. DOI: 10.1016/s0025-6196(12)62059-x. View

Pollak C, Minar E, Dragosics B, Marosi L . [Primary biliary cirrhosis and scleroderma: long-term benign course of a complex autoimmune disease]. Leber Magen Darm. 1985; 15(2):85-9. View

Beswick D, KLATSKIN G, Boyer J . Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. Gastroenterology. 1985; 89(2):267-71. View

10.

Modena V, Marengo C, Amoroso A, Rosina F, Costantini P, Bellando P . Primary biliary cirrhosis and rheumatic diseases: a clinical, immunological and immunogenetical study. Clin Exp Rheumatol. 1986; 4(2):129-34. View

11.

Powell F, Schroeter A, Dickson E . Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med. 1987; 62(237):75-82. View

12.

Steen V, Powell D, Medsger Jr T . Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988; 31(2):196-203. DOI: 10.1002/art.1780310207. View

13.

LeRoy E, Black C, FLEISCHMAJER R, Jablonska S, Krieg T, Medsger Jr T . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5. View

14.

Dickson E, Grambsch P, Fleming T, Fisher L, Langworthy A . Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989; 10(1):1-7. DOI: 10.1002/hep.1840100102. View

15.

Mitchison H, Lucey M, Kelly P, Neuberger J, Williams R, James O . Symptom development and prognosis in primary biliary cirrhosis: a study in two centers. Gastroenterology. 1990; 99(3):778-84. DOI: 10.1016/0016-5085(90)90968-7. View

16.

Hansen B, Eriksson S, Lindgren S . High prevalence of autoimmune liver disease in patients with multiple nuclear dot, anti-centromere, and mitotic spindle antibodies. Scand J Gastroenterol. 1991; 26(7):707-13. DOI: 10.3109/00365529108998588. View

17.

Marguerie C, Bunn C, Copier J, Bernstein R, GILROY J, Black C . The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore). 1992; 71(6):327-36. DOI: 10.1097/00005792-199211000-00001. View

18.

Maekawa S, Yano E, Shintani S . [A case of rheumatoid arthritis associated with progressive systemic sclerosis and primary biliary cirrhosis in the presence of various autoantibodies]. Ryumachi. 1992; 32(5):515-21. View

19.

Hughes M, Raskino C, Pocock S, Biagini M, Burroughs A . Prediction of short-term survival with an application in primary biliary cirrhosis. Stat Med. 1992; 11(13):1731-45. DOI: 10.1002/sim.4780111307. View

20.

Chou M, Lai M, Lee S, Tsay G . Reactivity of anti-mitochondrial antibodies in primary biliary cirrhosis and systemic sclerosis. J Formos Med Assoc. 1992; 91(11):1075-80. View